Our pharmaceutical drug development candidates are synthetic small-molecules designed to target key biochemical pathways involved in human diseases of critical unmet needs. We currently have four proprietary drug candidates under clinical development and two drug candidates under preclinical Close Studies done in animals or in cell cultures prior to testing a new drug in human clinical trials.
Preclinical
This includes an inhibitor of Bruton's tyrosine kinase Close A enzyme Close A type of protein Close A class of molecules (including enzymes, antibodies, or structural proteins) that are built from amino acid components to perform a wide range of functions in the cell. A genetic immunosuppressive disease in humans that results from a mutated and inactivated Btk gene. Cells involved in allergic and inflammatory response. One step in the drug approval process during which doctors establish the safety of a new drug and its best dose, administration, and regimen. An immune response by the body against its own cells or tissues. A series of coagulation factors that circulate outside the blood stream and in the environment surrounding tumors.
Bruton\'s tyrosine kinase
Enzyme
Protein
ImmunodeficiencyInherited condition caused mutation in genes that effect immune response. disease X-linked agammaglobulinemia Close
Agammaglobulinemia
Mast Cell
Phase I Clinical Trial
OncologyThe study and treatment of cancer.
applications; a series of Btk inhibitors in advanced preclinical lead optimization and testing targeting autoimmune Close
Autoimmune
Factor VIIa, Factor IXa, Factor Xa, Factor XI
Phase II Clinical TrialIn this phase of testing, doctors try to confirm the safety and dosing of the new drug as well as its effectiveness. and HDAC8 inhibitors (i.e PCI-34051 and others) that are currently being optimized for autoimmune and cancer indications. Motexafin gadolinium (MGd) has completed accrual in two Phase II trials being conducted by the National Cancer Institute (NCI) in patients with glioblastoma multiforme and pontine glioma.